The Journal of allergy and clinical immunology · 2026
First-trimester asthma controller medication use and major congenital malformation risk in offspring of women with asthma: A nationwide population-based cohort study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiao Xue-Feng, Leal Lisiane Freitas, Ducharme Francine M, Tse Sze Man, Bérard Anick
Аннотация
BACKGROUND: Evidence regarding the safety of asthma controller medications (particularly montelukast) for the fetus remains insufficient and controversial.
OBJECTIVE: We sought to comprehensively evaluate the association between first-trimester use of 5 common asthma controller regimens and the risk of major congenital malformations in the offspring of women with asthma.
METHODS: We conducted a population-based cohort study using data from the AMerican PREGNANcy Mother-Child CohorT (AM-PREGNANT) from 2003 to 2021, which primarily comprises individuals with private insurance coverage in the United States. Singleton live births to mothers with asthma were included. Exposure was based on first-trimester prescription fills for asthma controller medications. The outcomes included major congenital malformations overall, organ-specific malformations, and 2 specific defects.
RESULTS: We identified 44,435 eligible pregnancies. Compared with the no asthma controller medication group, none of the 5 controller medication groups (montelukast monotherapy, inhaled corticosteroid [ICS] monotherapy, ICS + long-acting β2-adrenergic agonist [LABA] combination, montelukast + ICS combination, montelukast + ICS + LABA combination) was associated with an increased risk of major congenital malformations. The montelukast + ICS combination group was associated with an increased risk of cleft palate and/or lip compared with the no asthma controller medication group, but the number of events was limited (<5).
CONCLUSIONS: Among pregnant women with asthma, first-trimester exposure to any of the 5 common asthma controller regimens in this study was not associated with an increased risk of major congenital malformations. Further studies are needed to confirm the association between the montelukast + ICS combination regimen and the risk of cleft palate and/or lip.
OBJECTIVE: We sought to comprehensively evaluate the association between first-trimester use of 5 common asthma controller regimens and the risk of major congenital malformations in the offspring of women with asthma.
METHODS: We conducted a population-based cohort study using data from the AMerican PREGNANcy Mother-Child CohorT (AM-PREGNANT) from 2003 to 2021, which primarily comprises individuals with private insurance coverage in the United States. Singleton live births to mothers with asthma were included. Exposure was based on first-trimester prescription fills for asthma controller medications. The outcomes included major congenital malformations overall, organ-specific malformations, and 2 specific defects.
RESULTS: We identified 44,435 eligible pregnancies. Compared with the no asthma controller medication group, none of the 5 controller medication groups (montelukast monotherapy, inhaled corticosteroid [ICS] monotherapy, ICS + long-acting β2-adrenergic agonist [LABA] combination, montelukast + ICS combination, montelukast + ICS + LABA combination) was associated with an increased risk of major congenital malformations. The montelukast + ICS combination group was associated with an increased risk of cleft palate and/or lip compared with the no asthma controller medication group, but the number of events was limited (<5).
CONCLUSIONS: Among pregnant women with asthma, first-trimester exposure to any of the 5 common asthma controller regimens in this study was not associated with an increased risk of major congenital malformations. Further studies are needed to confirm the association between the montelukast + ICS combination regimen and the risk of cleft palate and/or lip.